BESPOKE Study of ctDNA Guided Immunotherapy

Completed

Conditions studied: Colorectal Cancer, Melanoma, Non-small Cell Lung Cancer

In brief

This is a prospective data collection study of patients with advanced solid tumors who will receive standard of care immunotherapy (IO) and will be monitored with SIGNATERA™ testing. SIGNATERA™ test will be performed at baseline and during routine care. The test results will be part of assessing tumor response. The correlation between SIGNATERA™ test results and subsequent treatment decisions will be examined to compare actual treatment delivered against treatment decisions potentially impacted by SIGNATERA™ results. Treatment administered, tumor assessment results, time to progression, overall survival, physician questionnaires, and patient-reported outcomes will be collected/recorded.

Key facts

Study ID
NCT04761783
Run by
Natera, Inc.
People needed
290
Starts
2021-05-28
Expected to finish
2024-03-30
Last updated by the study team
2024-08-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.